Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
Sorrento Announces Phase II Results Of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress Of The European Society For Medical Oncology
IMC-001, a PD-L1 monoclonal antibody selected from Sorrento's G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response
Sorrento Announces Arbitrator In Nantcell/NANTibody Arbitration Issued Award Granting Contractual Damages, Pre-award Interest Of $156.8M To Nantcell; Award Also Held That Co Has No Further Obligations Under Exclusive License Agreement With NANTibody
As previously disclosed, Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) has been engaged in arbitration before the American Arbitration Association against NantCell, Inc.
Sorrento Touts Positive Early-Stage Trial Data From Oral COVID-19 Therapy
Sorrento Therapeutics Inc (NASDAQ:SRNE) released topline Phase 2 SAD/MAD study data of its oral main protease (Mpro) inhibitor, STI-1558, conducted in…
Sorrento Releases Topline Results From The Phase I Study Completed In Australia And Preliminary Results From A Phase Ib Study In China With STI-1558, An Oral M(pro) Inhibitor As A Standalone Treatment For COVID-19 Without The Need For Ritonavir Boostin…
Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending dose (MAD) study of STI-1558 in 58 healthy volunteers in Australia are now available. The SAD portion of the
Scilex Holding Company, A Sorrento Company And Vickers Vantage Corp. I Announce Effectiveness Of Registration Statement On Form S-4, Date Of Vickers Vantage Extraordinary General Meeting To Approve Proposed Business Combination
SEC declared Effectiveness of Vickers's registration statement on Form S-4
Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held
Sorrento Successfully Completes Phase 1 Study And Is Proceeding To Implement Global Registrational Trials With STI-1558, An Oral Mpro Inhibitor As A Standalone Oral Treatment And Prevention Of COVID-19 Without The Need For A Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg and 2,000 mg doses in the single ascending dose (SAD) portion of the study and 300 mg, 600 mg and 800 mg
Sorrento Announces Publication Of Data In Cell Press Journal Med Describing Discovery And Preclinical Efficacy Of A Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) Or IN (STI-9199)
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling